title: Acute change in parathyroid function in primary hyperparathyroidism following ultrasonically guided ethanol injection into solitary parathyroid adenomas.
abstract: Ultrasonically guided percutaneous injection of 96% ethanol into solitary parathyroid tumours in patients with primary hyperparathyroidism may be used as an alternative to surgery in selected patients. Contrary to surgical parathyroidectomy, the acute changes in parathyroid function following ultrasound-guided chemical parathyroidectomy have never been described. Seven consecutive and highly selected patients with primary hyperparathyroidism were treated with ultrasonically guided injection of ethanol (96%) into solitary and biopsy-verified parathyroid tumours. Basic treatment included a maximum of three injections separated by intervals of 24 h. In six of the seven patients normal serum values of ionized calcium were achieved within 36-120 h (median 36 h) and normal serum values of intact parathyroid hormone within 6-78 h (median 24 h). Three patients received two injections and three patients three injections. One patient remained hypercalcaemic in spite of three injections. Subsequent surgery showed the patient to have two parathyroid adenomas, of which only one had been detected ultrasonically. The present study has demonstrate a fast normalization of parathyroid function following two to three ethanol injections into solitary parathyroid tumors in selected patients with primary hyperparathyroidism.
authors.affiliation: Department of Ultrasound and Internal Medicine, Herlev Hospital, University of Copenhagen, Denmark.
authors.forename: S
authors.initials: S
authors.lastname: Karstrup
authors.forename: L
authors.initials: L
authors.lastname: Hegedüs
authors.forename: H H
authors.initials: HH
authors.lastname: Holm
mesh_terms: D000236:Adenoma / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D000368:Aged; D000369:Aged, 80 and over; D002118:Calcium / Q000097:blood; D000431:Ethanol / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006934:Hypercalcemia / Q000209:etiology; D006961:Hyperparathyroidism / Q000188:drug therapy* / Q000209:etiology; D015552:Injections, Intralesional; D008875:Middle Aged; D010280:Parathyroid Glands / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000378:metabolism; D010281:Parathyroid Hormone / Q000096:biosynthesis; D010282:Parathyroid Neoplasms / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000378:metabolism; D013997:Time Factors; D014463:Ultrasonography
chemical_list: D010281:Parathyroid Hormone; D000431:Ethanol; D002118:Calcium